Claims
- 1. A pharmaceutical composition comprising a compound of the formula ##STR45## or a pharmaceutically acceptable salt thereof wherein X is --CH.dbd.CH--;
- wherein R.sup.1 is --CO.sub.2 R.sup.2 ;
- wherein R.sup.2 is hydrogen, alkyl of 1 to 6 carbons or a pharmaceutically acceptable cation;
- wherein R is an alkyl of from 1 to 20 carbons, --(CH.sub.2).sub.p CF.sub.3 or --(CH.sub.2).sub.q R.sup.3 wherein R.sup.3 is alkoxy, phenoxy or alkoxy substituted phenoxy wherein the alkoxy group has from 1 to 8 carbons;
- wherein p and q are integers from 0 to 20;
- wherein n is 1; and
- wherein m is 0, 1, 2, or 3;
- and a pharmaceutically acceptable carrier.
- 2. A method for the treatment of mammals exhibiting an LTB.sub.4 mediated inflammatory condition, comprising administering a compound of the formula ##STR46## or a pharmaceutically acceptable salt thereof wherein X is --CH.dbd.CH--;
- wherein R.sup.1 is --CO.sub.2 R.sup.2 ;
- wherein R.sup.2 is hydrogen, alkyl of 1 to 6 carbons or a pharmaceutically acceptable cation;
- wherein R is an alkyl of from 1 to 20 carbons, --(CH.sub.2).sub.p CF.sub.3 or --(CH.sub.2).sub.q R.sup.3 wherein R.sup.3 is alkoxy, phenoxy or alkoxy substituted phenoxy wherein the alkoxy group has from 1 to 8 carbons;
- wherein p and q are integers from 0 to 20;
- wherein n is 1; and
- wherein m is 0, 1, 2, or 3.
- 3. A pharmaceutical composition according to claim 1 wherein m is zero.
- 4. A pharmaceutical composition according to claim 1 wherein R.sup.1 is --CO.sub.2 H.
- 5. A pharmaceutical composition according to claim 1 wherein R comprises an alkyl group of 10 to 15 carbons.
- 6. A pharmaceutical composition according to claim 5 wherein the compound is 3-(1,3-dioxohexadecanyl)benzoic acid.
- 7. A pharmaceutical composition according to claim 5 wherein the compound is 4-(1,3-dioxohexadecanyl)benzoic acid.
- 8. A method according to claim 2 wherein m is zero.
- 9. A method according to claim 2 wherein R.sup.1 is --CO.sub.2 H.
- 10. A method according to claim 2 wherein R comprises an alkyl group of 10 to 15 carbons.
- 11. A method according to claim 10 wherein the compound is 3-(1,3-dioxohexadecanyl)benzoic acid.
- 12. A method according to claim 10 wherein wherein the compound is 4-(1,3-dioxohexadecanyl)benzoic acid.
Parent Case Info
This is a CONTINUATION of prior application Ser. No. 07/707,522 filed on May 30, 1991 now U.S. Pat. No. 5,356,919.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
3255241 |
Schultz et al. |
Jun 1966 |
|
3912656 |
Andrews et al. |
Oct 1975 |
|
3919250 |
Pauling et al. |
Nov 1975 |
|
4015010 |
Houlihan et al. |
Mar 1977 |
|
4381360 |
Leistner et al. |
Apr 1983 |
|
4469885 |
Mueller et al. |
Sep 1984 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
142145 |
May 1985 |
EPX |
282898 |
Sep 1988 |
EPX |
1457025 |
Dec 1976 |
GBX |
Non-Patent Literature Citations (3)
Entry |
Fackler, Progress Inorg. Chem., "Metal .beta.-Ketoenolate Complexes" pp. 361-425 (1966). |
Singh, et al., Progress in Medicinal Chem., vol. 17, Elseveer, Chap. 4-Medicinal Chem. of Tetrazoles, pp. 151-183 (1980). |
Thornber, Chem. Society Reviews, vol. 8, pp. 563-580 (1979). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
707522 |
May 1991 |
|